Caplacizumab as an Emerging Treatment for Patients With Thrombotic Thrombocytopenic Purpura Presenting With Acute Ischemic Stroke

Neurology Clinical Practice 2026 Open access

Read full text
Authors: Konstantinos Melanis, Aikaterini Theodorou, Lina Palaiodimou, Eleni Bakola, Maria Chondrogianni, Georgios Tsikalakis, Niki Nana, Maria Sora, Alexandros-Stavros Triantafyllou, V. Pappa, Sotirios G. Papageorgiou, Panagiotis Tsirigotis
+2 more Eleni Gavriilaki, Georgios Tsivgoulis
DOI: 10.1212/cpj.0000000000200580
Cited by: 2
References: 15

Abstract

Objectives: Thrombotic thrombocytopenic purpura (TTP) is rare, life-threatening autoimmune disorder characterized by microvascular thrombosis, severe thrombocytopenia, and hemolytic anemia. It can lead to organ ischemia and increase the risk of thromboembolic events, including acute ischemic stroke (AIS). Caplacizumab, an essential adjunct in TTP management, rapidly inhibits platelet aggregation and prevents disease progression. Methods: We present 3 cases of TTP diagnosed in patients with AIS. Treatment included plasma exchange (PLEX), corticosteroids, and caplacizumab. Results: All 3 patients exhibited acute neurologic deficits, with brain MRI confirming AIS. Laboratory tests revealed thrombocytopenia, hemolytic anemia, and ADAMTS-13 activity

Fields of Study & Subjects

Complement system in diseases Coagulation Bradykinin Polyphosphates and Angioedema Blood groups and transfusion

Publication details

Journal / source
Neurology Clinical Practice
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
16
Issue
2
Pages
e200580–e200580
Publication date
14 January 2026
Language
EN